86,249 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by Walleye Capital LLC

Walleye Capital LLC purchased a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 86,249 shares of the company’s stock, valued at approximately $3,122,000. Walleye Capital LLC owned 0.31% of Eton Pharmaceuticals as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Opaleye Management Inc. boosted its holdings in shares of Eton Pharmaceuticals by 0.3% in the second quarter. Opaleye Management Inc. now owns 2,860,000 shares of the company’s stock valued at $40,755,000 after acquiring an additional 7,930 shares during the period. EcoR1 Capital LLC increased its holdings in shares of Eton Pharmaceuticals by 7.0% in the 1st quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after acquiring an additional 141,394 shares during the period. Vanguard Group Inc. increased its holdings in shares of Eton Pharmaceuticals by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,344,115 shares of the company’s stock valued at $29,208,000 after acquiring an additional 31,942 shares during the period. State Street Corp raised its position in Eton Pharmaceuticals by 14.5% in the 4th quarter. State Street Corp now owns 501,925 shares of the company’s stock valued at $8,488,000 after purchasing an additional 63,480 shares during the last quarter. Finally, Millennium Management LLC raised its position in Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after purchasing an additional 217,042 shares during the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $58.86 on Friday. The stock has a market capitalization of $1.61 billion, a P/E ratio of 154.89 and a beta of 0.86. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. Eton Pharmaceuticals, Inc. has a 1 year low of $14.27 and a 1 year high of $59.79. The company’s fifty day moving average is $39.06 and its two-hundred day moving average is $28.59.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, August 13th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.11 by $0.32. The company had revenue of $37.59 million during the quarter, compared to analysts’ expectations of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 47.64%. On average, sell-side analysts predict that Eton Pharmaceuticals, Inc. will post 0.67 earnings per share for the current year.

Eton Pharmaceuticals News Roundup

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Quarterly results significantly exceeded expectations: Eton reported adjusted earnings of approximately $0.35–$0.43 per share, compared with consensus estimates ranging from $0.11 to $0.15. Revenue reached $37.59 million, well above the $27.11 million analyst forecast, and the company improved from a loss in the year-ago period. Eton Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Strong commercial growth supported the beat: Product sales nearly doubled year over year, increasing 99% in the second quarter. Management raised 2026 revenue guidance to more than $145 million and reiterated a long-term opportunity to generate over $500 million in peak annual sales through organic growth, pipeline products and acquisitions in rare diseases. Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability expectations are improving: Eton expects adjusted EBITDA margins above 35% in 2026, potentially reaching 50% by 2028, while gross margins are projected to expand from roughly 70% to more than 75%. These targets reinforce the market’s view that revenue growth could translate into substantial earnings growth. Eton Pharmaceuticals: No Reason Pharma Can’t Deliver More Great Earnings Like These
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $65 price target, suggesting continued upside potential, although its estimates imply investors will be focused on whether Eton can sustain the pace of growth.
• Negative Sentiment: HC Wainwright reduced its long-term EPS forecasts for 2027–2030, including lowering its 2030 estimate to $6.53 from $8.65. The revisions create a counterpoint to the upbeat quarterly results and highlight execution and valuation risks after the stock’s rapid advance. HC Wainwright Issues Negative Outlook for ETON Earnings

Analysts Set New Price Targets

ETON has been the subject of a number of recent research reports. B. Riley Financial reiterated a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday. Zacks Research cut shares of Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Canaccord Genuity Group raised their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a report on Friday. Finally, HC Wainwright boosted their price target on Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Friday. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $67.50.

Insider Transactions at Eton Pharmaceuticals

In related news, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at $1,624,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider David Krempa sold 42,797 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the completion of the sale, the insider owned 25,249 shares of the company’s stock, valued at approximately $843,064.11. The trade was a 62.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 150,000 shares of company stock worth $4,853,921. Company insiders own 16.49% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.